retatrutide what is it clinical trial for weight loss: Study shows 30% body weight loss ESC 2024: Retatrutide improves lipid

Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through -catenin

The compound is still working through Eli Lilly's TRIUMPH Phase 3 program, with seven additional trial readouts expected through 2026 alongside the already-reported TRIUMPH-4 data from December 2025

The research was published Monday in The Lancet Diabetes & Endocrinology

MI=myocardial infarction

Because GCGR activation is associated with changes in hepatic energy metabolism and lipid oxidation pathways, Retatrutide provides a framework for studying how multiple endocrine signaling inputs influence whole-body energy partitioning in controlled experimental environments [5]